乳鐵蛋白是II型糖尿病人患致死性心臟缺血的預警因子-技術前沿-資訊-生物在線

乳鐵蛋白是II型糖尿病人患致死性心臟缺血的預警因子

作者:北京經緯博恒生物科技開發有限責任公司 2011-05-16T00:00 (訪問量:48554)

Lactoferrin is a novel predictor of fatal ischemic heart disease in diabetes mellitus type 2: long-term follow-up of the HUNT 1 study.
Vengen IT, Dale AC, Wiseth R, Midthjell K, Videm V.
SourceDepartment of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, and Department of Cardiology, Trondheim University Hospital, Trondheim, Norway.

Abstract
OBJECTIVES: The pathogenesis of diabetes and atherosclerosis is linked through inflammation. Neutrophils contribute to atherosclerotic plaque development, and are dysfunctional in diabetes. The aim of this study was to compare the predictive values of two neutrophil degranulation products, myeloperoxidase and lactoferrin, on long-term risk for fatal ischemic heart disease in persons with newly diagnosed diabetes and controls.

DESIGN: Prospective population-based cohort study.

SETTING AND PATIENTS: In 1984-1986, a large population study, HUNT 1, was conducted in Norway. Previously unknown diabetes was diagnosed in 205 persons. A matched control group without diabetes was selected from the HUNT 1.

MAIN OUTCOME MEASURES: Fatal ischemic heart disease was registered until 2004. Baseline serum was analysed for myeloperoxidase and lactoferrin. Cox regression analysis with adjustments for age, gender, hypertension, body mass index, established cardiovascular disease and total cholesterol was used to estimate hazard ratios for fatal ischemic heart disease.

RESULTS: In the diabetes group (200 subjects), the two highest tertiles of lactoferrin predicted fatal ischemic heart disease, hazard ratio 2.54 (95% CI, 1.00-6.45) and 4.06 (1.72-9.60). Myeloperoxidase did not predict death from ischemic heart disease in subjects with diabetes. In the controls (198 subjects), none of the biomarkers predicted fatal ischemic heart disease.

CONCLUSION: Increased baseline concentration of lactoferrin strongly predicted the long-term risk for fatal ischemic heart disease in patients with newly diagnosed diabetes. Based on the literature, we hypothesize that the increased concentrations may reflect neutrophil priming caused by hyperglycemia.

Atherosclerosis 2010;Oct;212(2):614-20
北京經緯博恒生物科技開發有限責任公司 商家主頁

地 址: 北京市海淀區萬壽路街道太平路甲40號22樓411(軍醫科院南門).廊坊經濟技術開發區翠微南道29號(生產基地)

聯系人: 李經理

電 話: 業務:010-68167058,手機:18210299625

傳 真: 010-68167058

Email:genwaybh@163.com

相關咨詢
ADVERTISEMENT